The Hindu Business Line
Pfizer (Rs 632.90): BuyWe recommend a buy in Pfizer from a short-term perspective. From the chart, we see that it had been on a medium-term downtrend from December 2007 high of Rs 850 to mid-February low of Rs 587. However, the stock’s medium-term downtrend got ... More
Pfizer (Rs 632.90): BuyWe recommend a buy in Pfizer from a short-term perspective. From the chart, we see that it had been on a medium-term downtrend from December 2007 high of Rs 850 to mid-February low of Rs 587. However, the stock’s medium-term downtrend got ... More
The Economic Times
Stocks to pick: SBI, Infosys Technologies, Crompton Greaves, GLaxosmithkline
| State Bank of India | Research: HSBC | Rating: Underweight | CMP: Rs 2,115 | |
| Infosys Technologies | Research: Indiabulls Financials | Rating: Buy | CMP: Rs 1,580 | |
| Crompton Greaves | Research: JM Financials | Rating: Buy | CMP: Rs 298 | |
| GLaxosmithkline Pharma | Research: Motilal Oswal | Rating: Buy | CMP: Rs 953 |
Comments